Explore All Access
Check if your research matches the topics covered in Annals of Oncology?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Annals of Oncology : Impact Factor & More
eISSN: 1569-8041pISSN: 0923-7534
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Annals of Oncology Key Metrics
CiteScore 
47.3
SNIP
6.79
Time to Accept
3
Mo
Time to Publish
View Chart Mo
Time to Publish
Sign up now and unlock a detailed chart of Time to publish for this journal
% of papers by time taken from submission to publication
0 to 3 months41%
4 to 6 months42%
7 to 9 months16%
Above 9 months1%
Did you find this useful?
Topics Covered on Annals of Oncology
Cancer
Chemotherapy
Assay
Lung cancer
Adjuvant
Germline
Breast cancer
Immunotherapy
Soft tissue
Neuroendocrine tumors
Immune checkpoint
Melanoma
Reactive oxygen species
Crizotinib
Toxicity
Central nervous system
Lung
Overall survival
Saliva
Clinical trial
Annals of Oncology Journal Specifications
| Overview | |
| Publisher | ELSEVIER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1990 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Annals of Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Annals of Oncology
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
- 1 Dec 2024
- Annals of oncology : official journal of the European Society for Medical Oncology
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC)
- 1 Dec 2024
- Annals of Oncology
Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study
- 1 Dec 2024
- Annals of Oncology
Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
- 1 Dec 2024
- Annals of Oncology
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”: [Ann Oncol 35 (2024) 1039-1047]
- 1 Dec 2024
- Annals of Oncology
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.
- 1 Dec 2024
- Annals of oncology : official journal of the European Society for Medical Oncology
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
- 1 Dec 2024
- Annals of oncology : official journal of the European Society for Medical Oncology
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC)
- 1 Dec 2024
- Annals of Oncology
Pembrolizumab Versus chemotherapy in microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase 3 KEYNOTE-177 study
- 1 Dec 2024
- Annals of Oncology
Author’s reply to the Letters to the Editor. Six years duration of adjuvant imatinib in high-risk GIST: more to come
- 1 Dec 2024
- Annals of Oncology
Corrigendum to “Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma”: [Ann Oncol 35 (2024) 1039-1047]
- 1 Dec 2024
- Annals of Oncology
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.
- 1 Dec 2024
- Annals of oncology : official journal of the European Society for Medical Oncology
Compare Similar Journals with Annals of Oncology
Select Journals to Compare with Annals of Oncology
Total journals - 8
You can select up to 3 Journals at a time
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Cancers
Publisher: MDPI
European Journal of Cancer
Publisher: ELSEVIER SCI LTD
BMC Cancer
Publisher: BMC
Clinical Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
ESMO Open
Publisher: ELSEVIER
0 Journals Selected to compare with
Annals of Oncology
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Annals of Oncology
How long has Annals of Oncology been actively publishing? 
Annals of Oncology has been in operation since 1990 till date.
What is the publishing frequency of Annals of Oncology?
Annals of Oncology published with a Monthly frequency.
How many articles did Annals of Oncology publish last year?
In 2023, Annals of Oncology publsihed 4296 articles.
What is the eISSN & pISSN for Annals of Oncology?
For Annals of Oncology, eISSN is 1569-8041 and pISSN is 0923-7534.
What is Citescore for Annals of Oncology?
Citescore for Annals of Oncology is 47.3.
What is SNIP score for Annals of Oncology?
SNIP score for Annals of Oncology is 6.79.
Who is the publisher of Annals of Oncology?
ELSEVIER is the publisher of Annals of Oncology.
